Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-300, MEK inhibitor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARRY-300 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| ARRY-300, MEK inhibitor; oral | DRUG | single dose, escalating |
| Placebo | DRUG | matching placebo |
Key Inclusion Criteria: * Healthy male or female (females must be of non-childbearing potential) between the ages of 18 and 50 years, inclusive. * Body mass index (BMI) of 18 kg/m2 to 35 kg/m2; and a total body weight \> 50 kg (110 lbs) and \< 113 kg (280 lbs). * Additional criteria exist. Key Exc...
ARRY-300 is an oral small molecule drug candidate developed by Pfizer, Inc. (ticker PFE). It is an inhibitor that targets MET. It has been studied in a Phase 1 clinical trial in healthy adult subjects, and it is investigational rather than an approved medicine.
ARRY-300 targets MET. It is an inhibitor of that molecular target, and it is described as a small molecule drug candidate. The MET target is the basis for how ARRY-300 is designed to act, and the compound has been tested in a Phase 1 study in healthy subjects.
Pfizer, Inc. is the developer of ARRY-300. The company trades under the ticker PFE. Pfizer has advanced ARRY-300 into Phase 1 clinical development, where it has been evaluated in a single completed study of healthy adult subjects.
ARRY-300 is in Phase 1 development. It is an investigational drug candidate and is not approved. One Phase 1 trial of ARRY-300 has been completed, and no active trials are ongoing. The completed study enrolled 12 healthy adult subjects.
ARRY-300 has been studied in one completed Phase 1 trial, NCT00828165, titled A Safety Study of ARRY-300 in Healthy Subjects. That trial enrolled 12 healthy adult participants in the United States. It was randomized, double blind, and placebo controlled.
ARRY-300 is also referred to as ARRY-300, MEK inhibitor, and it is described as an oral drug candidate. These names refer to the same compound developed by Pfizer, Inc. (ticker PFE). It targets MET and has been evaluated in a completed Phase 1 study in healthy subjects.